Related references
Note: Only part of the references are listed.PLINK: A tool set for whole-genome association and population-based linkage analyses
Shaun Purcell et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2007)
A new multipoint method for genome-wide association studies by imputation of genotypes
Jonathan Marchini et al.
NATURE GENETICS (2007)
A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC
Paul I. W. de Bakker et al.
NATURE GENETICS (2006)
Case-only analysis of treatment-covariate interactions in clinical trials
E. Vittinghoff et al.
BIOMETRICS (2006)
Principal components analysis corrects for stratification in genome-wide association studies
Alkes L. Price et al.
NATURE GENETICS (2006)
Evaluating and improving power in whole-genome association studies using fixed marker sets
Itsik Pe'er et al.
NATURE GENETICS (2006)
Pharmacovigilance in a genomic era
P. Farahani et al.
PHARMACOGENOMICS JOURNAL (2006)
Design of case-controls studies with unscreened controls
V Moskvina et al.
ANNALS OF HUMAN GENETICS (2005)
Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002 - The importance of reporting suspected reactions
DK Wysowski et al.
ARCHIVES OF INTERNAL MEDICINE (2005)
HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol
SL Hung et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Disease-specific target selection: a critical first step down the right road
AD Roses et al.
DRUG DISCOVERY TODAY (2005)
A single-nucleotide polymorphism tagging set for human drug metabolism and transport
KR Ahmadi et al.
NATURE GENETICS (2005)
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan
F Innocenti et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations
AR Hughes et al.
PHARMACOGENOMICS (2004)
Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity:: A molecular and clinical study of 75 patients
E Rouits et al.
CLINICAL CANCER RESEARCH (2004)
Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients
M Pirmohamed et al.
BMJ-BRITISH MEDICAL JOURNAL (2004)
A Gilbert's syndrome UGT1A1 variant confers susceptibility to tranilast-induced hyperbilirubinemia
TM Danoff et al.
PHARMACOGENOMICS JOURNAL (2004)
Statistical significance for genomewide studies
JD Storey et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Cytochrome p450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis
YS Huang et al.
HEPATOLOGY (2003)
Genetic variations in HLA-B region and hypersensitivity reactions to abacavir
S Hetherington et al.
LANCET (2002)
Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir
S Mallal et al.
LANCET (2002)
Risk of cardiovascular events associated with selective COX-2 inhibitors
D Mukherjee et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Adverse drug reactions: definitions, diagnosis, and management
IR Edwards et al.
LANCET (2000)
Share Paper
